Respuesta limitada de los estrógenos en la mujer transexual (página 2)

14. Carmeci C, Thompson DA, Ring
HZ, Francke U, Weigel RJ. Identification of a gene (GPR30)
with homology to the G-protein-coupled receptor superfamily
associated with estrogen receptor expression in breast
cancer. Genomics. 1997;45:607–617.

15. Castelo-Branco C, Guerra A,
Blümel JE, et al. Piel y Menopausia: efectos de la edad,
estado hormonal y tratamientos. Rev Chil Obstet Ginecol 2000;
65: 143-51.

16. De Leo V, Lanzetta D, D"Antona
D, et al. Transdermal estrogen replacement therapy in normal
perimenopausal women: effects on pituitary-ovarian function.
Gynecol Endocrinol 1996; 10: 49-53.

17. Dechering K, Boersma C,
Mosselman S. Estrogen receptors alpha and beta: two receptors
of a kind? Curr Med Chem. 2000;7:561–576.

18. Delmas PD. Effects of
raloxifene on bone mineral density, serum cholesterol
concentrations, and uterine endometrium in post-menopausal
women. N Engl J Med 1997; 337:1641-1647.

19. Dietel M, Lewis MA, Shapiro S.
Hormone repla-cement therapy: pathobiological aspects of
hormone-sensitive cancers in women relevant to
epidemiologi-cal studies on HRT: a mini-review. Hum Reprod
2005 Aug; 20(8): 2052-2060•

20. Dupuy AM. Lipid levels and
cardiovascular risk in elderly women. CLIMATERIC
2008;11:74-83.

21. Fisher B, Costantino JP,
Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, et
al. Tamoxifen for Prevention of Breast Cancer: Report of the
Na-tional Surgical Adjuvant Breast and Bowel Project P-1
Study. J Natl Cancer Inst 1998; 90:
1371–1388•

22.  Gobeil F, Fortier A, Zhu T,
Bossolasco M, Leduc M, Grandbois M, Heveker N, Bkaily G,
Chemtob S, Barbaz D. G-protein-coupled receptors signalling
at the cell nucleus: an emerging paradigm. Can J Physiol
Pharmacol. 2006;84:287–297.

23. Govind AP, Thampan RV.
Membrane associated estrogen receptors and related proteins:
localization at the plasma membrane and the endoplasmic
reticulum. Mol Cell Biochem.
2003;253:233–240.

24. Gray RH. Biological and social
interactions in determination of late fertility. J Biosoc Sci
1979; suppl 6: 97-115.

25. Greene GL, Gilna P, Waterfield
M, Baker A, Hort Y, Shine J. Sequence and expression of human
estrogen receptor complementary DNA. Science.
1986;231:1150–1154.

26. Greene JG. Constructing a
standard climacteric scale. Maturitas 1998; 29:
25-31.

27. Gustafsson JA. What
pharmacologists can learn from recent advances in estrogen
signalling. Trends Pharmacol Sci.
2003;24:479–485.

28. Hall JM, Couse JF, Korach KS.
The multifaceted mechanisms of estradiol and estrogen
receptor signaling. J Biol Chem.
2001;276:36869–36872.]

29. Health plan for the adult
woman. International Menopause Society.Taylor & Francis
2005. pg 41-42.

30. Hewitt SC, Korach KS.
Oestrogen receptor knockout mice: roles for oestrogen
receptors alpha and beta in reproductive tissues.
Reproduction. 2003;125:143–149.

31. Ho KJ, Liao JK Nonnuclear
actions of estrogen. Arterioscler Thromb Vasc Biol.
2002;22:1952–1961.

32. http://www.medicamentosplm.com/productos/primogyn_grageas.htm.
PLM 2012

33. Lobo R. Is low dose hormonal
replacement efficacious and desirable? Climacteric 2001;
4:110-119. Updated practical recomendations for hormona
replacement therapy in the peri and postmenopause. CLIMATERIC
2008; 11:108-123.

34. Mac Lean AB, Nicol LA,
Hodgings MB, Inmuno-histoquimical of estrogen receptors in
the vulva and vagina. Reprod Med. 1999:35:
1015-1016.

35. Magnes RR. Ovarian secretion
and vascular funtion. En: Naftolin F, editor. Ovarian
secretions and cardiovascular and neurogical funtions. Nueva
York: Raven Press; 1990.p.93-125.

36. Marín F. Moduladores
selectivos del receptor estrogénico: nuevas
perspectivas para el tratamiento de la menopausia.
Endocrinología 1997; 44:311-314.

37. Moore RA Livial: review of
Clinical studies. Br J Obstet Gynaecol 1999 :106:
1-21.

38. Nakayama Y, Sakamoto H, Satoh
K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon
cancer growth in association with inhibition of thymidylate
synthase, survivin and telomerase expression through estrogen
receptor beta mediated system. Cancer Lett 2000 Dec 8;
161(1): 63-71•

39. Palacios S, Menéndez C.
Alteraciones del tracto génito-urinario bajo y
menopausia. En: Palacios S, editor. Climaterio y menopausia,
Madrid: Grefol SA; 1992.p.105-109

40. Panay N. HRT: does the dose
matter? CLIMACTERIC 2008; 11:177-178.

41. Panyakhamlerd K,
Chotnopparatpattara P, Taechakraichana N, et al. Skin
thickness in different menopausal status. Journal of the
Medical Association of Thailand 1999;82: 352-6.

42. Picariello L, Fiorelli G,
Martineti V, Tognarini I, Pam-paloni B, Tonelli F, Brandi ML.
Growth response of colon cancer cell lines to selective
estrogen receptor modula-tors. Anticancer Res 2003 May-Jun;
23(3B): 2419-2424

43. Qiu Y, Langman MJS and Eggo
MC. Targets of 17b-oestradiol-induced apoptosis in colon
cancer cells: a me-chanism for the protective effects of
hormone replace-ment therapy? J Endocrinol 2004; 181:
327–337

44. Salzer H, Schneider WH, Eppel
W. Contraception in preclimacteric women with special regard
to oral contraceptives. Wien Med Wochenschr 1980; 130:
218-21.

45. Sarrel PM, Sarrel LJ. Orgasmic
difficulties. The role of the gynecolist Clicn Obstet
Gynecol. North Am. 1978;21:181-203

46. Semmens JP, W Agner G.
Estrogen deprivation and vaginal funtion in postmenopausal
women. JAMA. 1982;248:445-448

47. Siseles N .Información
y formación para el manejo actual de la mujer en su
climaterio. Editorial Ascune 2005.

48. Sitruk Ware R.New hormonal
therapies and regimens in the postmenopause: routes of
administration and timing of initiation.CLIMACTERIC 2007;
10:358-370.

49. Speroff L. A risk-benefit
analisys of elective bilateral oophorectomy effect of changes
in compliance with estrogen therapy on outcome. Am J Obstet
Gynecol. 1991:164-165.

50. Studd J, Smith R. Oestrogens
and depresion in women. The Diplomate 1994;
1:18-23.

51. Utian W H. Rol de la
hormonoterapia a largo plazo en el contexto de la medicina
preventiva para la mujer postmenopáusica. En:
González Campos O, Arteaga Urzúa E, Contreras
Castro P, editores. Menopausia y patologías asociadas,
prevención y tratamiento. Santiago de Chile: Editorial
Bywaters; 1998.p.23-33

52. Utian W H. The menopause and
climateric. En: Phillip E, editor. Scientific Fundation of
Obstetrics and Gynecology. 4ª edición. Oxfor:
Butterworth-Heineman; 1991.p.199-207.

53. Utian WH. Síntomas
definitivos de la postmenopausia: incorporación del
uso del índice vaginal de células parabasales.
Front Horm Res. 1975;3:75-95

54. Utian Wh. The true clinical
features of postmenopause and oophorectomy, and their
response to oestrogen therapy. S Afr Med J. 1972; 46:
732-7.

55. Van Winter JT, Bernard ME.
Oral contraceptive use during the perimenopausal years. Am
Fam Physician 1998; 58: 1373-7.

56. Van-Hasften M, Donker GH,
Haspel AA, Thijssen JH. Oestrogen concentrations in plasma,
endometrium, miometrium and vagina of menopausal women and
effect of oestriol and estradiol aplications. J Steroid
Biochem. 1989;33:647-653

57. Vogel HG. Mecanical properties
of rat skin with ageing. En: Balin Ak, Kligman AM, editores.
Aging and the skin. Nueva York: Raven Press;
1989.p.227-275

58. Wiklunk I, Karlberg J,
Mattsson Lars-Ake. Quality of life of postmenopausal women on
a regimen of transdermal estradiol therapy: A double-blind
placebo-controlled study. Am J Obstet Gynecol.
1993;168:824-830

59. Yabur JA. Epidemiología
de la menopausia en Venezuela. En: Terán Dávila
J, Febres Balestrini F. editores. Medicina del climaterio y
la menopausia. Caracas: Editorial Ateproca;
1999.p.1-14.